Northern Trust’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.2M | Buy |
2,504,781
+274,669
| +12% | +$1.88M | ﹤0.01% | 1711 |
|
|
2025
Q4 | $4.42M | Buy |
2,230,112
+225,824
| +11% | +$512K | ﹤0.01% | 2543 |
|
|
2025
Q3 | $4.93M | Buy |
2,004,288
+159,927
| +9% | +$412K | ﹤0.01% | 2514 |
|
|
2025
Q2 | $4.87M | Buy |
1,844,361
+486,219
| +36% | +$1.31M | ﹤0.01% | 2468 |
|
|
2025
Q1 | $4.09M | Buy |
1,358,142
+34,718
| +3% | +$105K | ﹤0.01% | 2530 |
|
|
2024
Q4 | $3.39M | Buy |
1,323,424
+97,348
| +8% | +$406K | ﹤0.01% | 2740 |
|
|
2024
Q3 | $4.56M | Buy |
1,226,076
+84,314
| +7% | +$390K | ﹤0.01% | 2534 |
|
|
2024
Q2 | $7.22M | Sell |
1,141,762
-169,027
| -13% | -$1.11M | ﹤0.01% | 2186 |
|
|
2024
Q1 | $7.04M | Sell |
1,310,789
-46,270
| -3% | -$210K | ﹤0.01% | 2273 |
|
|
2023
Q4 | $6.81M | Buy |
1,357,059
+204,302
| +18% | +$641K | ﹤0.01% | 2321 |
|
|
2023
Q3 | $1.95M | Sell |
1,152,757
-8,942
| -0.8% | -$18K | ﹤0.01% | 2958 |
|
|
2023
Q2 | $3.23M | Buy |
1,161,699
+350,006
| +43% | +$990K | ﹤0.01% | 2738 |
|
|
2023
Q1 | $1.48M | Sell |
811,693
-3,580
| -0.4% | -$11.1K | ﹤0.01% | 3077 |
|
|
2022
Q4 | $4.13M | Buy |
815,273
+4,384
| +0.5% | +$24.1K | ﹤0.01% | 2603 |
|
|
2022
Q3 | $4.03M | Buy |
810,889
+56,015
| +7% | +$255K | ﹤0.01% | 2623 |
|
|
2022
Q2 | $2.81M | Buy |
754,874
+87,504
| +13% | +$351K | ﹤0.01% | 2863 |
|
|
2022
Q1 | $3.75M | Sell |
667,370
-17,157
| -3% | -$105K | ﹤0.01% | 2750 |
|
|
2021
Q4 | $4.16M | Sell |
684,527
-573,872
| -46% | -$4.31M | ﹤0.01% | 2803 |
|
|
2021
Q3 | $12.3M | Sell |
1,258,399
-90,296
| -7% | -$994K | ﹤0.01% | 2133 |
|
|
2021
Q2 | $19.3M | Buy |
1,348,695
+866,888
| +180% | +$14.3M | ﹤0.01% | 1910 |
|
|
2021
Q1 | $11.4M | Buy |
481,807
+79,536
| +20% | +$2.06M | ﹤0.01% | 2211 |
|
|
2020
Q4 | $5.36M | Buy |
402,271
+11,487
| +3% | +$110K | ﹤0.01% | 2648 |
|
|
2020
Q3 | $2.71M | Buy |
390,784
+6,620
| +2% | +$66K | ﹤0.01% | 2899 |
|
|
2020
Q2 | $4.72M | Buy |
384,164
+308,693
| +409% | +$1.74M | ﹤0.01% | 2563 |
|
|
2020
Q1 | $218K | Buy |
75,471
+14,462
| +24% | +$72.4K | ﹤0.01% | 3661 |
|
|
2019
Q4 | $232K | Buy |
61,009
+3,793
| +7% | +$6.45K | ﹤0.01% | 3742 |
|
|
2019
Q3 | $69K | Sell |
57,216
-216,983
| -79% | -$269K | ﹤0.01% | 3999 |
|
|
2019
Q2 | $280K | Sell |
274,199
-13,430
| -5% | -$15.5K | ﹤0.01% | 3718 |
|
|
2019
Q1 | $455K | Buy |
287,629
+3,509
| +1% | +$4.41K | ﹤0.01% | 3565 |
|
|
2018
Q4 | $329K | Sell |
284,120
-1,370
| -0.5% | -$3.13K | ﹤0.01% | 3650 |
|
|
2018
Q3 | $1.06M | Buy |
285,490
+3,604
| +1% | +$11.4K | ﹤0.01% | 3459 |
|
|
2018
Q2 | $862K | Sell |
281,886
-25,057
| -8% | -$92.8K | ﹤0.01% | 3482 |
|
|
2018
Q1 | $1.19M | Sell |
306,943
-6,896
| -2% | -$30.2K | ﹤0.01% | 3329 |
|
|
2017
Q4 | $1.41M | Sell |
313,839
-8,396
| -3% | -$39.8K | ﹤0.01% | 3295 |
|
|
2017
Q3 | $1.77M | Buy |
322,235
+18,173
| +6% | +$112K | ﹤0.01% | 3248 |
|
|
2017
Q2 | $2.31M | Buy |
304,062
+122,906
| +68% | +$531K | ﹤0.01% | 3093 |
|
|
2017
Q1 | $643K | Sell |
181,156
-2,109
| -1% | -$10.4K | ﹤0.01% | 3475 |
|
|
2016
Q4 | $1.05M | Buy |
183,265
+1,143
| +0.6% | +$7.63K | ﹤0.01% | 3336 |
|
|
2016
Q3 | $1.42M | Buy |
182,122
+27,951
| +18% | +$209K | ﹤0.01% | 3224 |
|
|
2016
Q2 | $959K | Buy |
154,171
+80,781
| +110% | +$627K | ﹤0.01% | 3356 |
|
|
2016
Q1 | $604K | Buy |
73,390
+138
| +0.2% | +$1.3K | ﹤0.01% | 3413 |
|
|
2015
Q4 | $1.27M | Buy |
73,252
+55,634
| +316% | +$825K | ﹤0.01% | 3237 |
|
|
2015
Q3 | $202K | Buy |
+17,618
| New | +$384K | ﹤0.01% | 3740 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Northern Trust's IBRX Position: Q1 2026 in Review
Northern Trust increased its ImmunityBio (IBRX) stake by 12% in Q1 2026, buying an estimated $1.88M and bringing the position to 2,504,781 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1711.
Northern Trust first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $19.3M in Q2 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Northern Trust held 2,504,781 shares of ImmunityBio worth $19.2M as of Q1 2026.
- Northern Trust bought 274,669 ImmunityBio shares in Q1 2026, an estimated $1.88M.
- ImmunityBio made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1711 holding.
- Northern Trust first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
- Northern Trust's ImmunityBio position peaked at $19.3M in Q2 2021.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.